Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130


Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.

Borgan E, Lindholm EM, Moestue S, Mælandsmo GM, Lingjærde OC, Gribbestad IS, Børresen-Dale AL, Engebraaten O, Sørlie T.

Mol Oncol. 2013 Feb;7(1):130-42. doi: 10.1016/j.molonc.2012.10.005. Epub 2012 Oct 23.


Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.

Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O.

Mol Oncol. 2012 Aug;6(4):418-27. doi: 10.1016/j.molonc.2012.03.006. Epub 2012 Mar 31.


Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.

Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Børresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS.

BMC Cancer. 2010 Aug 17;10:433. doi: 10.1186/1471-2407-10-433.


Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS.

J Magn Reson Imaging. 2013 Nov;38(5):1043-53. doi: 10.1002/jmri.24079. Epub 2013 Mar 21.


Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O.

Clin Cancer Res. 2014 Jan 15;20(2):404-12. doi: 10.1158/1078-0432.CCR-13-1865. Epub 2013 Nov 5.


Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS.

Breast Cancer Res. 2014 Jan 21;16(1):R5. doi: 10.1186/bcr3597.


13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns.

Grinde MT, Moestue SA, Borgan E, Risa Ø, Engebraaten O, Gribbestad IS.

NMR Biomed. 2011 Dec;24(10):1243-52. doi: 10.1002/nbm.1683. Epub 2011 Apr 4.


Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.

Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, Shirane M, Yamashita Y, Mori K.

Cancer Chemother Pharmacol. 2010 Jul;66(2):269-76. doi: 10.1007/s00280-009-1160-0. Epub 2009 Nov 11.


Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK.

Clin Cancer Res. 2013 Apr 1;19(7):1773-83. doi: 10.1158/1078-0432.CCR-12-1281. Epub 2013 Jan 10.


Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).

Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M.

Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Review.


Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.

du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16.


Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G.

Br J Cancer. 2008 Jul 8;99(1):93-9. doi: 10.1038/sj.bjc.6604429. Epub 2008 Jun 24.


18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.

McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.

J Nucl Med. 2009 Nov;50(11):1848-56. doi: 10.2967/jnumed.109.067231. Epub 2009 Oct 16.


Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.

Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H.

Dis Colon Rectum. 2011 Aug;54(8):1026-35. doi: 10.1097/DCR.0b013e31821c44af.


Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M.

Clin Cancer Res. 2008 Dec 1;14(23):7781-9. doi: 10.1158/1078-0432.CCR-08-0243.


Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.

Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Sweep FC, Geurts-Moespot A, Engelhardt MS, van der Graaf WT, Oyen WJ, van Laarhoven HW.

Mol Pharm. 2014 Nov 3;11(11):4249-57. doi: 10.1021/mp500460g. Epub 2014 Oct 17.


Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.

Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, Engebråten O, Gribbestad IS, Bjørkøy G.

Breast Cancer Res. 2013 Feb 28;15(1):R16. doi: 10.1186/bcr3391.


Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM.

Clin Cancer Res. 2007 Jul 1;13(13):3942-50.

Supplemental Content

Support Center